会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • 1-BENZOYL-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES
    • 作为用于治疗心脏病的甘油摄取抑制剂的1-苯甲酰基哌嗪衍生物
    • WO2005023261A1
    • 2005-03-17
    • PCT/EP2004/009699
    • 2004-08-31
    • F. HOFFMANN-LA ROCHE AGALBERATI-GIANI, DanielaJOLIDON, SyneseNARQUIZIAN, RobertNETTEKOVEN, Matthias, HeinrichNORCROSS, Roger, DavidPINARD, EmmanuelSTALDER, Henri
    • ALBERATI-GIANI, DanielaJOLIDON, SyneseNARQUIZIAN, RobertNETTEKOVEN, Matthias, HeinrichNORCROSS, Roger, DavidPINARD, EmmanuelSTALDER, Henri
    • A61K31/496
    • C07D295/16A61K31/495A61K31/496C07D213/56C07D213/69C07D213/74C07D233/64C07D239/26C07D239/42C07D241/12C07D251/42C07D251/48C07D257/04C07D263/32C07D277/30C07D295/185C07D309/04C07D309/20C07D333/24C07D409/12
    • The invention relates to compounds of formula (I) wherein Ar is substituted aryl or unsubstituted or substituted 6-membered heteroaryl, containing one, two or three nitrogen atoms, and wherein the aryl and the heteroaryl groups may be substituted by one or more substituents selected from the group consisting of hydroxy, halogen, CN, (C 1 ­C 6 )-alkyl, (C 1 -C 6 )-alkyl substituted by halogen, (C 1 -C 6 )-alkoxy, (C 1 -C 6 )-alkoxy substituted by halogen, NR 7 R 8 , C(O)R 9 or SO 2 R 10 ; R 1 is hydrogen or (C 1 -C 6 )-alkyl; R 2 is halogen, (C 1 -C 6 ) -alkyl, (C 2 -C 6 ) -alkenyl, wherein a hydrogen atom may be replaced by CN, C(O)-R 9 or (C 1 -C 6 )-alkyl, or is (C 2 -C 6 )­alkynyl, (C 1 -C 6 )-alkyl substituted by halogen, -(CH 2 ) n -(C 3 -C 7 )-cycloalkyl, -(CH 2 ) n -heterocycloalkyl, -C(O)-R 9 , -(CH 2 ) n -aryl or -(CH 2 ) n -5 or -6­membered heteroaryl containing one, two or three heteroatoms, selected from the group consisting of oxygen, sulphur or nitrogen wherein aryl, cycloalkyl, heterocycloalkyl and heteroaryl are unsubstituted or substituted by one or more substituents selected from the group consisting of hydroxy, halogen, (C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl substituted by halogen or (C 1 -C 6 ) alkoxy; R 3 , R 4 and R 6 independently from each other are hydrogen, hydroxy, halogen, (C 1 -C 6 )-alkyl or (C 1 -C 6 )-alkoxy; R 5 is NO 2 , CN, C(O)R 9 , SO 2 R 10 or NR 11 R 12 ; R 7 and R 8 independently from each other are hydrogen or (C 1 -C 6 )-alkyl; the other substituents are defined in the claims; and to pharmaceutically acceptable acid addition salts thereof for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
    • 本发明涉及式(I)化合物,其中Ar是含有一个,两个或三个氮原子的取代的芳基或未取代或取代的6元杂芳基,其中芳基和杂芳基可以被一个或多个选自 由羟基,卤素,CN,(C 1 -C 6) - 烷基,被卤素取代的(C 1 -C 6) - 烷基,(C 1 -C 6) - 烷氧基,被卤素取代的(C 1 -C 6) - 烷氧基,NR 7 R 8,C(O)R 9或SO 2 R 10; R 1是氢或(C 1 -C 6) - 烷基; R 2是卤素,(C 1 -C 6) - 烷基,(C 2 -C 6) - 烯基,其中氢原子可以被CN,C(O)-R 9或(C 1 -C 6) - 烷基 或(C 2 -C 6)炔基,被卤素, - (CH 2)n - (C 3 -C 7) - 环烷基, - (CH 2)n - 杂环烷基,-C(O)-R 含有一个,两个或三个选自氧,硫或氮的杂原子的(CH 2)n - 芳基或 - (CH 2)n-5或 - (CH 2)n-5或-6元杂芳基,其中芳基,环烷基,杂环烷基和 杂芳基是未取代的或被一个或多个选自羟基,卤素,(C 1 -C 6) - 烷基,被卤素或(C 1 -C 6)烷氧基取代的(C 1 -C 6) R 3,R 4和R 6彼此独立地是氢,羟基,卤素,(C 1 -C 6) - 烷基或(C 1 -C 6) - 烷氧基; R 5是NO 2,CN,C(O)R 9,SO 2 R 10或NR 11 R 12; R 7和R 8彼此独立地是氢或(C 1 -C 6) - 烷基; 其它取代基在权利要求中限定; 以及其药学上可接受的酸加成盐,用于治疗精神病,疼痛,记忆和学习中的神经变性功能障碍,精神分裂症,痴呆和其他认知过程受损的其他疾病,如注意力缺陷障碍或阿尔茨海默病。
    • 6. 发明申请
    • PIPERIDINE-BENZENESULFONAMIDE DERIVATIVES
    • 哌嗪 - 苯甲酰胺衍生物
    • WO2004072034A1
    • 2004-08-26
    • PCT/EP2004/001211
    • 2004-02-10
    • F. HOFFMANN-LA ROCHE AGALBERATI-GIANI, DanielaCECCARELLI, Simona, MariaPINARD, EmmanuelSTALDER, Henri
    • ALBERATI-GIANI, DanielaCECCARELLI, Simona, MariaPINARD, EmmanuelSTALDER, Henri
    • C07D211/58
    • C07D413/12C07D211/58C07D401/08C07D401/12C07D405/04C07D405/12C07D409/12C07D413/14
    • The present invention relates to compounds of the general formula (I) wherein R 1 is lower alkyl, -(CH 2 ) n -aryl, unsubstituted or substituted by one or two substituents, selected from the group consisting of lower alkyl, lower alkoxy, -OCF 3 , halogen, -NR’R” or trifluoromethyl, or heteroaryl; R 2 is lower alkyl, -(CH 2 ) n -aryl, unsubstituted or substituted by one or two substituents, selected from the group consisting of lower alkyl, lower alkoxy, halogen, trifluoromethyl, nitro, cyano, -NR’R”, hydroxy, or by a heteroaryl group, or is heteroaryl, unsubstituted or substituted by one or two substituents, selected from the group consisting of lower alkyl or halogen; R 3 is heteroaryl or is aryl, unsubstituted or substituted by halogen or lower alkyl; R 4 is hydrogen or hydroxy; A is -S(O) 2 -or-C(O)-; X,Y are independently from each other -CH 2 - or -O-, with the proviso that X and Y are not simultaneously -O; R’R” are independently from each other hydrogen, lower alkyl or -C(O)-lower alkyl; n is 0, 1 or 2; and to pharmaceutically acceptable acid addition salts thereof. The compounds may be used for the treatment of psychoses, pain, disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer’s disease.
    • 本发明涉及通式(I)的化合物,其中R 1为低级烷基, - (CH 2)n - 芳基,未取代或被一个或两个选自以下的取代基取代:低级烷基,低级烷氧基 ,-OCF 3,卤素,-NR'R“或三氟甲基或杂芳基; R 2是低级烷基, - (CH 2)n - 芳基,未取代或被一个或两个取代基取代,所述取代基选自低级烷基 ,低级烷氧基,卤素,三氟甲基,硝基,氰基,-NR'R“,羟基或杂芳基,或是未被取代或被一个或两个选自低级烷基或卤素的取代基取代的杂芳基; R 3是杂芳基或未被取代或被卤素或低级烷基取代的芳基; R 4是氢或羟基; A是-S(O)2 - 或-C(O) - ; X,Y彼此独立地为-CH 2 - 或-O-,条件是X和Y不同时为-O; R'R“彼此独立地为氢,低级烷基或-C(O) - 低级烷基; n为0,1或2;以及其药学上可接受的酸加成盐。该化合物可用于治疗精神病 记忆障碍,学习障碍,精神分裂症,痴呆等认知过程受损的疾病,如注意力缺陷障碍或阿尔茨海默病。
    • 9. 发明申请
    • INHIBITORS FOR GLYT-1
    • GLYT-1的抑制剂
    • WO2008025694A1
    • 2008-03-06
    • PCT/EP2007/058610
    • 2007-08-20
    • F. HOFFMANN-LA ROCHE AGJOLIDON, SyneseNARQUIZIAN, RobertPINARD, Emmanuel
    • JOLIDON, SyneseNARQUIZIAN, RobertPINARD, Emmanuel
    • C07C233/51C07C235/52C07C235/56C07C237/40C07C255/57C07D213/56C07D213/61C07D213/74C07D261/18C07D333/70A61K31/166A61K31/167A61K31/44A61K31/381A61K31/415
    • C07C237/12C07C255/57C07D213/81C07D213/82C07D317/52C07D333/20C07D333/70
    • The present invention relates to compounds of the general formula I wherein R 1 is lower alkyl, aryl or heteroaryl, wherein aryl and heteroaryl are optionally substituted by halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, cyano, amino, di-lower alkyl amino or morpholinyl; R 2 is lower alkyl, -(CH 2 )n-aryl, -(CH 2 )n-heteroaryl or -(CH 2 )n-cycloalkyl, wherein the aryl or heteroaryl groups are optionally substituted by one or more substituents, selected from the group consisting of halogen, lower alkyl, cyano, or lower alkoxy; R 3 is hydrogen or lower alkyl; R 4 is aryl or heteroaryl, wherein at least one ring is aromatic in nature, wherein aryl and heteroaryl are optionally substituted by one or more substituents, selected from the group consisting of halogen, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, lower alkyl; X is a bond or -OCH 2 -; n is 0, 1 or 2; or to pharmaceutically acceptable acid addition salts thereof, with the exception of 4-methoxy-N-[2-oxo-2-(phenylamino)ethyl]-N-phenyl-benzamide, 4-chloro-N-[2-[(4-methylphenyl)amino]-2-oxoethyl]-N-phenyl-benzamide, 4-chloro-N-[2-[5-chloro-2-methoxyphenyl)amino]-2-oxoethyl]-N-benzamide, 4-methyl-N-(2-oxo-2-[(2,4,6-trichlorophenyl)amino]ethyl]-N-benzamide, N-[2-[(4-methylphenyl)amino]-2-oxoethyl]-N-phenyl-benzamide, 4-methyl-N-[2-[(4-methylphenyl)amino]-2-oxoethyl]-N-phenyl-benzamide, 4-chloro-N-(2-oxo-2-[(2,4,6-trichlorophenyl)amino]ethyl]-N-benzamide and N-[2-[(2, 4-dimethoxyphenyl)amino]-2-oxoethyl]-N-[(2-fluorophenyl)methyl]- benzeneacetamide. and to their use in the treatment of neurological and neuropsychiatric disorders.
    • 本发明涉及通式I的化合物,其中R 1是低级烷基,芳基或杂芳基,其中芳基和杂芳基任选被卤素,低级烷基,低级烷氧基,被卤素取代的低级烷基 由卤素,氰基,氨基,二低级烷基氨基或吗啉基取代的低级烷氧基; R 2是低级烷基, - (CH 2)2 - 芳基, - (CH 2 CH 2)n - 杂芳基或 - (CH
    • 10. 发明申请
    • 4-AMINO-1,5-SUBSTITUTED 1,5-DIHYDRO-IMIDAZOL-2-ONES
    • 4-氨基-1,5-取代的1,5-二氢-1H-咪唑-2-酮
    • WO2007101802A1
    • 2007-09-13
    • PCT/EP2007/051824
    • 2007-02-27
    • F. HOFFMANN-LA ROCHE AGJOLIDON, SyneseNARQUIZIAN, RobertNORCROSS, RogerPINARD, Emmanuel
    • JOLIDON, SyneseNARQUIZIAN, RobertNORCROSS, RogerPINARD, Emmanuel
    • C07D233/92A61K31/4025A61P25/18
    • C07D233/92
    • The present invention relates to compounds of the general formula wherein R 1 is -(CH 2 ) n -aryl or -(CH 2 ) n -heteroaryl, wherein such groups are unsubstituted or substituted by one or more substituents, selected from the group consisting of halogen, lower alkyl substituted by halogen, lower alkoxy, lower alkyl, cyano, nitro, -O-lower alkyl substituted by halogen or morpholinyl; R 2 is -(CH 2 ) n -aryl or -(CH 2 ) n -heteroaryl, wherein such groups are unsubstituted or substituted by one or more substituents, selected from the group consisting of lower alkyl, lower alkoxy, halogen or -N(lower alkyl) 2 ; R 3 is hydrogen or lower alkyl; R 4 is -(CH 2 ) n -aryl or -(CH 2 ) n -heteroaryl, wherein such groups are unsubstituted or substituted by one or more substituents, selected from the group consisting of halogen or lower alkoxy, or is lower alkyl, -(CH 2 ) n -cycloalkyl; or R 3 and R 4 form together with the N-atom a heterocyclic ring; n is 0, 1 or 2; and to pharmaceutically acceptable acid addition salts thereof. It has been found that the compounds of general formula I or their tautomeric forms are good inhibitors of the glycine transporter 1 (GIyT-1), and that they have a good selectivity to glycine transporter 2 (GIyT-2) inhibitors, useful for the treatment of schizophrenia.
    • 本发明涉及以下通式的化合物:其中R 1是 - (CH 2)n - 芳基或 - (CH 2) 其中这些基团是未取代的或被一个或多个选自以下的取代基取代:卤素,被卤素取代的低级烷基,低级烷氧基,低级烷基,低级烷氧基, 氰基,硝基,被卤素或吗啉基取代的-O-低级烷基; R 2是 - (CH 2)n - 芳基或 - (CH 2 2)n - 其中这些基团是未取代的或被一个或多个选自低级烷基,低级烷氧基,卤素或-N(低级烷基)2个取代基取代的取代基取代。 R 3是氢或低级烷基; R 4是 - (CH 2)n - 芳基或 - (CH 2)n - 其中这些基团是未取代的或被一个或多个选自卤素或低级烷氧基的取代基取代,或者是低级烷基, - (CH 2 CH 2) ñ - 环烷基; 或R 3和R 4形成与N-原子一起形成杂环; n为0,1或2; 及其药学上可接受的酸加成盐。 已经发现,通式I或其互变异构形式的化合物是甘氨酸转运蛋白1(GlyY-1)的良好抑制剂,并且它们对甘氨酸转运蛋白2(GlyT-2)抑制剂具有良好的选择性,可用于 治疗精神分裂症。